SYNVISTA THERAPEUTICS
| WVB Number: 32043NU | Country: United States of America |
| SIC categorization: PHARMACEUTICAL PREPARATIONS (2834) | ISIN: US02144G1076 |
| FT categorization: DRUGS (433) |
» Corporation Profile
| Profile in brief: The company is a product-based biopharmaceutical company engaged in the discovery and development of oral drugs for the treatment of diseases of aging and diabetes. |
|
| Phone: 1 201 934 5000 | Fax: 201 934 8880 |
| Chairman: NOAH BERKOWITZ | Auditor: J.H. COHN LLP |
| CEO/Managing Director: NOAH BERKOWITZ | |
» Company Facts
| Net Profit Margin (%) | -39,111.76 |
| Operating Margin (%) | -18,537.25 |
| Return on Assets (%) | -209.86 |
| Return on Equity (%) | -264.02 |
| Employees | 9 |
» Company Financials
| Annual (2007) | |
| Income Statement ('000 USD ) |
|
| Sales/Total Revenue | 51 |
| EBITDA | -9,902 |
| EBIT | -9,454 |
| Net Income | -19,947 |
| Balance Sheet ( '000 USD) |
|
| Total Current Assets | 15,880 |
| Total Assets | 16,705 |
| Total Current Liabilities | 2,837 |
| Total Liabilities & Debt | 2,837 |
| Total Equity | 13,868 |
| Cash Flow ( '000 USD) |
|
| Net Income/Starting Line | -19,947 |
| Cash from Operating | -15,430 |
| Cash from Investing | -323 |
| Cash from Financing | 29,920 |
| Cash & Equivalent Yr End | 15,646 |